GGrantIndex
← Search

PREVENTION-CONTROL

$36,525P30FY2015CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

PROJECT SUMMARY (See instructions): Members of the Cancer Prevention and Control Program (PC) conduct population sciences and chemoprevention research that has significant potential to reduce the cancer burden in Colorado, the Rocky Mountain Region and beyond. PC has three main focus groups: 1) behavioral research in primary and secondary prevention, 2) chemoprevention research, and 3) cancer outcomes and cancer survivorship research. During the current CCSG program members have made numerous contributions to the science of cancer prevention and control, including: 1) several large research clinical trials (RCTs) that have demonstrated the efficacy of tailored print materials to promote fruit and vegetable consumption, colorectal cancer screening and smoking cessation; 2) a large school-based program and a monumental effort that targeted the outdoor winter recreation industry that successfully promoted sun protection; 3) a robust program of laboratory research that has demonstrated the chemoprevention properties of silibinin in animal models for prostate, lung, colorectal, and bladder cancer, as well as grape seed extract for prostate and colon cancer; 4) a large multi-site RCT demonstrating the efficacy of telephone counseling on psychosocial outcomes among breast cancer survivors; 5) a large multi-site RCT that demonstrated the efficacy of a cognitive remediation program for young survivors of childhood cancer; 6) two of the most definitive programs of research in cancer epidemiology that have examined and identified risk factors for breast cancer among Latinas, and nevus development among young children in Colorado, and 7) numerous exemplars of translational science and dissemination research in the areas of sun protection, diet, nutrition and physical activity, tobacco control, colorectal cancer screening and chemoprevention research. PC includes 31 Full Members and 32 Associate Members drawn from 17 academic departments and schools within the University of Colorado Denver, University of Colorado Boulder, the Veterans Administration (Denver), Colorado State University, Denver Health Medical Center, The Children's Hospital (Denver) and Kaiser Permanente of Colorado. During the current CCSG, program members have published 594 peer-reviewed cancer-related papers, compared to 306 during the previous CCSG. 37% of these publications were collaborative, with 23% being interprogrammatic or both interprogrammatic and intraprogrammatic. Peer reviewed, cancer-related funding has also increased from $8.9M (2005) to $13.3M in 2010. This represents a per capita increase of 140% from $269K to over $640K per member.

View original record on NIH RePORTER →